Biopharmaceutical patent protection vs. generic drug competition: Traversing the public policy tightrope
Tài liệu tham khảo
Stivers, 2018
2018
2018
Letter, 2017
Aam, 2018
2018
2019
2019
Royzman, 2017
Ruschke, 2017
Quinn, 2018
2020
Davio, 2018
Noonan, 2019
Davio, 2017
2021
Walker, 2021, Biosimilar insulin gets new approval, Wall St. J., A5
2015
Iancu, 2019
2019
2011
Flibbert, 2015
Miller, 2017
eMedExpert, 2018
Niosi, 2017, Biosimilars in north America, Technol. Anal. Strat. Manag., 29, 290, 10.1080/09537325.2016.1254772
Bougher, 2010, 22
Zhai, 2019, Why are biosimilars not living up to their promise in the U.S, AMA Journal of Ethics, 21, 668, 10.1001/amajethics.2019.668